Cargando…

Broad-Spectrum Drugs Against Viral Agents

Development of antivirals has focused primarily on vaccines and on treatments for specific viral agents. Although effective, these approaches may be limited in situations where the etiologic agent is unknown or when the target virus has undergone mutation, recombination or reassortment. Augmentation...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopher, Mary E., Wong, Jonathan P.
Formato: Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635754/
https://www.ncbi.nlm.nih.gov/pubmed/19325820
http://dx.doi.org/10.3390/ijms9091561
_version_ 1782164227965845504
author Christopher, Mary E.
Wong, Jonathan P.
author_facet Christopher, Mary E.
Wong, Jonathan P.
author_sort Christopher, Mary E.
collection PubMed
description Development of antivirals has focused primarily on vaccines and on treatments for specific viral agents. Although effective, these approaches may be limited in situations where the etiologic agent is unknown or when the target virus has undergone mutation, recombination or reassortment. Augmentation of the innate immune response may be an effective alternative for disease amelioration. Nonspecific, broad-spectrum immune responses can be induced by double-stranded (ds)RNAs such as poly (ICLC), or oligonucleotides (ODNs) containing unmethylated deocycytidyl-deoxyguanosinyl (CpG) motifs. These may offer protection against various bacterial and viral pathogens regardless of their genetic makeup, zoonotic origin or drug resistance.
format Text
id pubmed-2635754
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-26357542009-03-25 Broad-Spectrum Drugs Against Viral Agents Christopher, Mary E. Wong, Jonathan P. Int J Mol Sci Review Development of antivirals has focused primarily on vaccines and on treatments for specific viral agents. Although effective, these approaches may be limited in situations where the etiologic agent is unknown or when the target virus has undergone mutation, recombination or reassortment. Augmentation of the innate immune response may be an effective alternative for disease amelioration. Nonspecific, broad-spectrum immune responses can be induced by double-stranded (ds)RNAs such as poly (ICLC), or oligonucleotides (ODNs) containing unmethylated deocycytidyl-deoxyguanosinyl (CpG) motifs. These may offer protection against various bacterial and viral pathogens regardless of their genetic makeup, zoonotic origin or drug resistance. Molecular Diversity Preservation International (MDPI) 2008-09-01 /pmc/articles/PMC2635754/ /pubmed/19325820 http://dx.doi.org/10.3390/ijms9091561 Text en © 2008 by MDPI http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Christopher, Mary E.
Wong, Jonathan P.
Broad-Spectrum Drugs Against Viral Agents
title Broad-Spectrum Drugs Against Viral Agents
title_full Broad-Spectrum Drugs Against Viral Agents
title_fullStr Broad-Spectrum Drugs Against Viral Agents
title_full_unstemmed Broad-Spectrum Drugs Against Viral Agents
title_short Broad-Spectrum Drugs Against Viral Agents
title_sort broad-spectrum drugs against viral agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635754/
https://www.ncbi.nlm.nih.gov/pubmed/19325820
http://dx.doi.org/10.3390/ijms9091561
work_keys_str_mv AT christophermarye broadspectrumdrugsagainstviralagents
AT wongjonathanp broadspectrumdrugsagainstviralagents